How is clinical research evolving in IPF and other rare respiratory diseases?

Clinical research in idiopathic pulmonary fibrosis (IPF) and rare respiratory diseases is moving beyond symptom management toward disease modification. Progress in cystic fibrosis, with mutation-targeted therapies improving life expectancy, and the emergence of disease-modifying agents in pulmonary arterial hypertension, highlights this shift. IPF remains challenging: approved antifibrotics slow decline, and heterogeneity complicates treatment timing and benefit prediction, though recent approvals and pivotal data signal momentum.

Accurate, early diagnosis, driven by multidisciplinary teams, is essential to initiate therapy before significant progression. To ease participation burden, trials increasingly incorporate home health and remote monitoring, bringing assessments closer to patients while maintaining oversight. Endpoint strategies are evolving from spirometry alone to patient-centered measures that reflect how individuals feel, function and survive. Precision medicine, including advanced phenotyping and biomarker-guided stratification, is aligning targeted therapies with subgroups most likely to benefit, balancing innovation with regulatory familiarity to improve feasibility and real-world relevance.

Watch the webinar to learn even more about today’s dynamic IPF and rare respiratory disease landscape, key clinical trial challenges, and proactive planning strategies for accelerating trial delivery and delivering success.